- Trial phase
- Preclinical
- Time to market
- At least 5-7 years away from potential approval, assuming successful IND filing in 2027, completion of Phase 1-3 trials, and regulatory review. The program has not yet entered human testing.
- Why 2/10
- No hard dated catalyst is scheduled in the next ~12 months. The IND filing is planned for 2027 without a specific date. BBP-717 is a preclinical program that represents a very small part of BridgeBio's large, diversified pipeline, which includes the approved drug Attruby and the late-stage BBP-418 with a PDUFA on November 27, 2026.
BBP-717 is too early-stage to drive near-term stock movement. The next catalyst to watch is the planned IND filing in 2027, but no specific date has been set. Investors should focus on BridgeBio's nearer-term catalysts: the BBP-418 PDUFA decision on November 27, 2026, and the commercial ramp of Attruby (acoramidis) for ATTR-CM.
Price Chart
Executive Summary
BBP-717 is a preclinical-stage monoclonal antibody program from BridgeBio Pharma (BBIO, Nasdaq) designed to deplete transthyretin (TTR) amyloid deposits in patients with ATTR cardiomyopathy (ATTR-CM). BridgeBio nominated BBP-717 as a development candidate in Q3 2026, announced on October 29, 2026, and plans to file an Investigational New Drug (IND) application with the FDA in 2027. The program is early-stage and represents a small component of BridgeBio's broader pipeline, which includes the already-approved ATTR-CM stabilizer Attruby (acoramidis) and the BBP-418 program with a PDUFA date of November 27, 2026. BBP-717 faces established competition from Alexion/AstraZeneca's ALXN2220 (cliramitug), which is already in a Phase 3 trial (DepleTTR-CM).
How It Works
BBP-717 is a monoclonal antibody (a type of lab-made protein that mimics the immune system's ability to fight targets) designed to bind to and help clear amyloid deposits -- abnormal clumps of misfolded protein -- that build up in the heart muscle of patients with ATTR cardiomyopathy. Unlike TTR stabilizers (like BridgeBio's approved drug Attruby) that prevent new amyloid from forming, BBP-717 aims to remove existing amyloid deposits, potentially enabling disease reversal.
Trial Status
BBP-717 is in preclinical development. BridgeBio nominated it as a development candidate in Q3 2026 and plans to submit an IND application to the FDA in 2027, with clinical trials projected to begin between 2027 and 2028.
The Two-Sided Case
Upcoming Catalysts
- IND filing planned for 2027 (no specific date announced)
- Advancement into clinical trials projected between 2027 and 2028
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BridgeBio Pharma, Inc. PRESS-RELEASE BBIO ·Originating report